CAV-1–Mediated Mitochondrial Cholesterol Metabolism Orchestrates Mitophagy and Tumor Suppression in Liver Cancer

Study Background and Research Question

Liver cancer remains a leading cause of cancer-related mortality worldwide, with hepatocellular carcinoma (HCC) comprising the majority of cases. Despite advances in systemic therapies, high recurrence rates and the emergence of drug resistance limit long-term efficacy. Current first-line agents, such as doxorubicin, regorafenib, and Sorafenib (BAY-43-9006), offer improved survival but are constrained by adverse effects and incomplete response rates. As dysregulated cholesterol metabolism has emerged as a metabolic vulnerability in liver cancer, a critical unmet need exists to elucidate novel mechanisms and therapeutic strategies that leverage organelle-specific lipid dynamics.

This research, published in Phytomedicine (April 2026), addresses the question: How does celastrol, a bioactive triterpenoid, modulate mitochondrial cholesterol metabolism to induce mitophagy and suppress HCC growth, and what molecular mediators are responsible for this effect?

Key Innovation from the Reference Study

The principal innovation of this investigation is the identification of the caveolin-1 (CAV-1)/sterol carrier protein-2 (SCP2) axis as a regulatory hub for mitochondrial cholesterol trafficking in liver cancer. The study demonstrates that celastrol triggers a redistribution of intracellular cholesterol, resulting in mitochondrial cholesterol overload. This process activates mitophagy, ultimately inhibiting tumor progression. Notably, the research highlights the mechanistic disruption of CAV-1/SCP2 interactions by celastrol as a novel regulatory event, providing a mechanistic link between cholesterol dysregulation, mitochondrial stress, and tumor suppression. These findings establish a new paradigm for targeting organelle-specific lipid homeostasis in oncology.

Methods and Experimental Design Insights

The study employed a comprehensive suite of techniques to dissect the molecular and cellular effects of celastrol in liver cancer models:

• Lipidomics and Imaging: Filipin staining and enzymatic assays were utilized to visualize and quantify alterations in mitochondrial cholesterol content following celastrol treatment.
• Transcriptomic and Proteomic Profiling: RNA sequencing identified changes in gene expression related to lipid metabolism and mitophagy. Validation was performed using RT-qPCR and Western blotting.
• Protein Interaction Studies: Co-immunoprecipitation assays clarified the impact of celastrol on the CAV-1/SCP2 complex, pinpointing a direct disruption of cholesterol trafficking machinery.
• Functional Assays: ROS measurement, mitochondrial membrane potential assays, and mitophagy markers were assessed to elucidate downstream consequences of cholesterol accumulation.
• In Vivo Validation: Xenograft models, including CAV-1 knockout mice, were used to confirm the physiological relevance of the observed mechanisms and the antitumor efficacy of celastrol.

Core Findings and Why They Matter

The study reported several pivotal findings (reference):

• Celastrol induces a marked intracellular redistribution of cholesterol, culminating in its accumulation within mitochondria.
• Disruption of CAV-1/SCP2 interaction impairs cholesterol export from mitochondria, directly linking celastrol to altered organelle lipid homeostasis.
• Mitochondrial cholesterol overload leads to elevated reactive oxygen species (ROS), dissipation of the mitochondrial membrane potential, and activation of mitophagy.
• These changes collectively suppress liver cancer cell proliferation and attenuate tumor growth in both wild-type and CAV-1 knockout xenograft models.

Importantly, by connecting mitophagy induction to mitochondrial cholesterol metabolism, the study illuminates a previously underappreciated therapeutic axis in liver cancer biology. This mechanistic insight complements established approaches that focus on kinase inhibition and antiangiogenic strategies, such as those employed by Sorafenib, by offering an orthogonal route to tumor suppression through metabolic and organelle-specific targeting. The findings thus expand the arsenal of actionable targets in cancer biology research, especially for drug-resistant or recurrent disease states.

Comparison with Existing Internal Articles

Several internal resources provide contextualization for the mechanistic breadth of Sorafenib (BAY-43-9006) in cancer biology research. For instance, the article "Sorafenib: Mechanistic Insights and Strategy for Translational Oncology" offers a detailed examination of Sorafenib’s multikinase inhibition, particularly its impact on the RAF/MEK/ERK pathway and receptor tyrosine kinases in hepatocellular carcinoma models. Similarly, "Sorafenib (BAY-43-9006): Translational Insights for Hepatocellular Carcinoma" discusses not only kinase pathway modulation but also highlights the need for integrated strategies that address metabolic and microenvironmental targets.

The present celastrol study complements these perspectives by introducing mitochondrial cholesterol metabolism as a targetable vulnerability, potentially synergistic with antiangiogenic agents or kinase inhibitors. While Sorafenib remains a cornerstone for tumor proliferation inhibition and angiogenesis blockade, the disruption of cholesterol homeostasis and induction of mitophagy introduce new research directions for combination or sequential therapy, especially in models demonstrating resistance to classical kinase inhibition.

Limitations and Transferability

While the study provides robust mechanistic evidence both in vitro and in vivo, several limitations warrant consideration:

• Model Specificity: The findings are primarily derived from established liver cancer cell lines and xenograft models, limiting immediate extrapolation to human clinical scenarios.
• Genetic Context: The exclusive use of CAV-1 knockout mice and the focus on the CAV-1/SCP2 axis may not capture the complexity of cholesterol trafficking in diverse tumor microenvironments or in the presence of additional genetic alterations.
• Therapeutic Translation: While celastrol shows promise as a modulator of mitochondrial cholesterol metabolism, its pharmacodynamics, toxicity, and combinatorial potential with approved agents like Sorafenib require further investigation in preclinical and clinical settings.

Nevertheless, the mechanistic clarity and reproducibility of the presented workflows support their adoption in cancer biology research, particularly for laboratories exploring organelle-targeted interventions or resistance mechanisms to established antiangiogenic agents.

Protocol Parameters

• Celastrol treatment: In vitro dosing should align with literature-backed concentrations (e.g., micromolar range) and exposure times (24–48 hours) for reliable induction of mitochondrial cholesterol accumulation and mitophagy.
• Lipid quantification: Filipin staining and enzymatic cholesterol assays are recommended for detecting mitochondrial cholesterol redistribution.
• Mitophagy assessment: Employ mitochondrial membrane potential assays (e.g., JC-1) and ROS measurement for functional readouts of organelle stress and mitophagy activation.
• Protein interaction analysis: Co-immunoprecipitation protocols should be optimized for CAV-1/SCP2 detection to delineate the disruption of cholesterol trafficking complexes.
• In vivo validation: Xenograft models, including CAV-1 knockout strains, are appropriate for confirming the physiological relevance of cholesterol-mediated mitophagy.
• For antiangiogenic or kinase inhibitor comparison: Sorafenib (see below) can be included in parallel experimental arms to dissect pathway-specific vs. metabolic effects in hepatocellular carcinoma models.

Research Support Resources

For researchers aiming to model antiangiogenic and antiproliferative mechanisms in liver cancer, Sorafenib (SKU A3009) from APExBIO is a widely used multikinase inhibitor that targets Raf-1, B-Raf, VEGFR2, and key receptor tyrosine kinases. Sorafenib is routinely applied in cancer biology research tools to interrogate the RAF/MEK/ERK pathway, angiogenesis, and downstream effects on cell proliferation and survival. According to the product information, it demonstrates reliable dose-dependent inhibition in hepatocellular carcinoma models and supports reproducibility in both cell-based and animal studies. When designing experiments to compare metabolic and kinase-dependent mechanisms, Sorafenib can serve as a benchmark inhibitor for pathway specificity and as a control in workflows exploring organelle-targeted strategies, such as those described in the present study.